In a story about chronic pain, Cannabis Patient Care cites OHSU evidence review published in 2022 that found thin evidence behind cannabis-related products to treat chronic pain.

Mark Pennesi, M.D., Ph.D., is the lead researcher of an Endogena Therapeutics-sponsored Phase 1/2a clinical trial for a potential treatment for the blindness-causing condition retinitis pigmentosa.

The Lund Report covers unionizing effort by research workers at OHSU.

The Bulletin (Bend) says OHSU’s and St. Charles Health’s joint efforts to establish a new family medicine residency program in Central Oregon beginning in 2024 “needs to be celebrated” because it “aims to help address the critical gap in rural healthcare.”

Alison Edelman M.D., M.P.H., shares insight on the safety and efficacy of Opill, a birth control pill designed to be used safely without a prescription. Edelman was part of the team that studied how the pill performed at baseline and what happens if a dose is missed or taken late. She says, “Progestin-only pills like Opill are safe in most people, which makes them a great option for over-the-counter use.”

Nature reports on news from the United Kingdom that babies have been born in a clinical trial underway to prevent the transmission of mitochondrial disease from parents to children, a type of therapy developed by Shoukhrat Mitalipov, Ph.D., at OHSU.

The Lund Report spoke with OHSU research workers who would like to form a union.

David Spencer, M.D., discusses the importance of patient safety in a first-in-human trial of NRTX-1001 GABAergic interneuron cell therapy for focal epilepsy.

A story about a National Academies report that finds gaps in NIH-supported nonhuman primate research undermine U.S. biomedical research and public health, Jon Hennebold, Ph.D., says: “There has been an increased recognition of the importance of these models in biomedical research,” including studies related to infectious diseases, neuroscience and reproductive and developmental health.

Continued media coverage of Guinness World Records certifying that OHSU dermatologists detected the world’s smallest skin cancer, measuring just .65 millimeters. In an interview with The Washington Post, Alexander Witkowski, M.D., Ph.D., says: “We want to share this knowledge with the next generation as this realm of health care begins to change — I think in a good way.”